A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
收藏Mendeley Data2024-01-31 更新2024-06-27 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009371/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple myeloma (MM) regimens in participants with MM as measured by overall response rate (ORR) or very good partial response (VGPR) or better rate.
创建时间：
2024-01-31
